AVD-话题@MedSci

#AVD#

7篇内容 | 1303人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2235013, encodeId=7da32235013aa, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a> <a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a>, objectTitle=纳武利尤单抗+AVD治疗晚期经典霍奇金淋巴瘤, objectType=article, longId=849761, objectId=a163849e6100, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a163849e6100, replyNumber=0, likeNumber=40, createdTime=2024-11-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a163849e6100, moduleTitle=纳武利尤单抗+AVD治疗晚期经典霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a163849e6100)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2231881, encodeId=2336223188118, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a> <a href='/topic/show?id=094be82196d' target=_blank style='color:#2F92EE;'>#经典型霍奇金淋巴瘤#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a>, objectTitle=新英格兰医学杂志：纳武利尤单抗+AVD对比BV+AVD治疗进展期经典型霍奇金淋巴瘤的3期研究, objectType=article, longId=847710, objectId=555984e71042, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240629/1719591134161_5579292.jpg, objectUrl=/article/show_article.do?id=555984e71042, replyNumber=0, likeNumber=0, createdTime=2024-10-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=555984e71042, moduleTitle=新英格兰医学杂志：纳武利尤单抗+AVD对比BV+AVD治疗进展期经典型霍奇金淋巴瘤的3期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=555984e71042)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1352940, encodeId=60961352940fb, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a>, objectTitle=J Clin Oncol：Brentuximab Vedotin联合AVD一线治疗早期不良霍奇金淋巴瘤的疗效优于标准疗法, objectType=article, longId=734317, objectId=5093e34317c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5093e34317c1, replyNumber=0, likeNumber=101, createdTime=2022-08-05, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5093e34317c1, moduleTitle=J Clin Oncol：Brentuximab Vedotin联合AVD一线治疗早期不良霍奇金淋巴瘤的疗效优于标准疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5093e34317c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1352939, encodeId=fd5a135293954, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a>, objectTitle=J Clin Oncol：布伦妥昔单抗联合AVD方案治疗新确诊的有不良预后风险的早期霍奇金淋巴瘤, objectType=article, longId=210662, objectId=e920210662a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e920210662a8, replyNumber=0, likeNumber=92, createdTime=2021-05-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e920210662a8, moduleTitle=J Clin Oncol：布伦妥昔单抗联合AVD方案治疗新确诊的有不良预后风险的早期霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e920210662a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1352938, encodeId=9fef135293898, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a>, objectTitle=Blood：派姆单抗序贯AVD化疗可有效治疗经典霍奇金淋巴瘤, objectType=article, longId=201701, objectId=2194201e0180, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2194201e0180, replyNumber=0, likeNumber=83, createdTime=2020-10-07, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2194201e0180, moduleTitle=Blood：派姆单抗序贯AVD化疗可有效治疗经典霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2194201e0180)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1352937, encodeId=82b5135293e20, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a>, objectTitle=中心点：第3年时，A+AVD疗法展现出明显优于ABVD疗法的效果，且与PET2状态无关。在预先指定的亚组中也观察到了A+AVD疗法相对于ABVD疗法的收益，, objectType=article, longId=186674, objectId=c1271866e48e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1271866e48e, replyNumber=0, likeNumber=81, createdTime=2020-01-24, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1271866e48e, moduleTitle=中心点：第3年时，A+AVD疗法展现出明显优于ABVD疗法的效果，且与PET2状态无关。在预先指定的亚组中也观察到了A+AVD疗法相对于ABVD疗法的收益，, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1271866e48e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1352936, encodeId=1a9b135293629, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a>, objectTitle=抗体-药物偶联物：加拿大批准ADCETRIS与AVD联合化疗用于初治型晚期霍奇金淋巴瘤, objectType=article, longId=165419, objectId=c229165419d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c229165419d1, replyNumber=0, likeNumber=103, createdTime=2019-05-07, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c229165419d1, moduleTitle=抗体-药物偶联物：加拿大批准ADCETRIS与AVD联合化疗用于初治型晚期霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c229165419d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1352935, encodeId=1b721352935ba, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a>, objectTitle=姜文奇教授：Brentuximab Vedotin联合AVD一线治疗中晚期霍奇金淋巴瘤可显著改善无复发生存, objectType=article, longId=123411, objectId=11981234112e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11981234112e, replyNumber=0, likeNumber=92, createdTime=2017-12-16, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11981234112e, moduleTitle=姜文奇教授：Brentuximab Vedotin联合AVD一线治疗中晚期霍奇金淋巴瘤可显著改善无复发生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11981234112e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1352934, encodeId=82731352934ca, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a>, objectTitle=JACC：中度主动脉瓣混合性病变（MAVD）患者预后较差, objectType=article, longId=68615, objectId=aeaa6861558, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeaa6861558, replyNumber=0, likeNumber=70, createdTime=2016-05-20, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeaa6861558, moduleTitle=JACC：中度主动脉瓣混合性病变（MAVD）患者预后较差, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeaa6861558)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

AVD

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#霍奇金淋巴瘤# #AVD# #纳武利尤单抗#

纳武利尤单抗+AVD治疗晚期经典霍奇金淋巴瘤

2024-11-04发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#AVD# #经典型霍奇金淋巴瘤# #纳武利尤单抗#

新英格兰医学杂志：纳武利尤单抗+AVD对比BV+AVD治疗进展期经典型霍奇金淋巴瘤的3期研究

2024-10-20发表于上海

zhaojie88 (审核中...)

前往app查看评论内容

#AVD#

J Clin Oncol：Brentuximab Vedotin联合AVD一线治疗早期不良霍奇金淋巴瘤的疗效优于标准疗法

2022-08-05

zhaojie88 (审核中...)

前往app查看评论内容

#AVD#

J Clin Oncol：布伦妥昔单抗联合AVD方案治疗新确诊的有不良预后风险的早期霍奇金淋巴瘤

2021-05-01

zhaojie88 (审核中...)

前往app查看评论内容

#AVD#

Blood：派姆单抗序贯AVD化疗可有效治疗经典霍奇金淋巴瘤

2020-10-07

zhaojie88 (审核中...)

前往app查看评论内容

#AVD#

中心点：第3年时，A+AVD疗法展现出明显优于ABVD疗法的效果，且与PET2状态无关。在预先指定的亚组中也观察到了A+AVD疗法相对于ABVD疗法的收益，

2020-01-24

zhaojie88 (审核中...)

前往app查看评论内容

#AVD#

抗体-药物偶联物：加拿大批准ADCETRIS与AVD联合化疗用于初治型晚期霍奇金淋巴瘤

2019-05-07

zhaojie88 (审核中...)

前往app查看评论内容

#AVD#

姜文奇教授：Brentuximab Vedotin联合AVD一线治疗中晚期霍奇金淋巴瘤可显著改善无复发生存

2017-12-16

zhaojie88 (审核中...)

前往app查看评论内容

#AVD#

JACC：中度主动脉瓣混合性病变（MAVD）患者预后较差

2016-05-20

科室
- - 订阅+
  - 更多科室
工具
服务